ESMO TAT 2021 | ZENITH20: Poziotinib efficacy and safety in NSCLC

Adrian Sacher, MD, MMSc, FRCPC, Princess Margaret Cancer Centre, Toronto, ON, shares results from the Phase II ZENITH20 study (NCT03318939) study of poziotinib efficacy and safety in patients with EGFR, or HER2 exon 20 mutant non-small cell lung cancer (NSCLC). Dr. Sacher focuses on a cohort with untreated NSCLC with the EGFR exon 20 mutation, where 91% of patients have a reduced tumor size and the overall response rate was 27.8%. Dr. Sacher reports on another cohort receiving twice-daily dosing, which improved tolerability and similar efficacy. This interview took place during the ESMO TAT 2021 conference.